(Total Views: 757)
Posted On: 02/11/2022 3:41:13 PM
Post# of 148892
NYTimes
A monoclonal antibody drug from Eli Lilly that has promise against Omicron gets emergency authorization.
HOW does this get an EUA and we don't????
The rates of COVID-19 related hospitalization and death through Day 29 seen in those who received bebtelovimab alone or with other monoclonal antibodies were generally lower than the placebo rate reported in prior trials of other monoclonal antibodies in high risk patients. Conclusions are limited as these data are from different trials that were conducted when different viral variants were circulating and baseline risk factors varied.
Clinical data were similar for bebtelovimab alone as compared to the combination of bebtelovimab with other monoclonal antibodies.
Possible side effects of bebtelovimab include itching, rash, infusion-related reactions, nausea and vomiting.
Serious and unexpected adverse events including hypersensitivity, anaphylaxis and infusion-related reactions have been observed with other SARS-CoV2 monoclonal antibodies and could occur with bebtelovimab. In addition, clinical worsening following administration of other SARS-CoV-2 monoclonal antibody treatment has been reported and therefore is possible with bebtelovimab. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19.
Side effects and it doesn't work. We are up against Big Pharma and the FDA, always have been.
A monoclonal antibody drug from Eli Lilly that has promise against Omicron gets emergency authorization.
HOW does this get an EUA and we don't????
The rates of COVID-19 related hospitalization and death through Day 29 seen in those who received bebtelovimab alone or with other monoclonal antibodies were generally lower than the placebo rate reported in prior trials of other monoclonal antibodies in high risk patients. Conclusions are limited as these data are from different trials that were conducted when different viral variants were circulating and baseline risk factors varied.
Clinical data were similar for bebtelovimab alone as compared to the combination of bebtelovimab with other monoclonal antibodies.
Possible side effects of bebtelovimab include itching, rash, infusion-related reactions, nausea and vomiting.
Serious and unexpected adverse events including hypersensitivity, anaphylaxis and infusion-related reactions have been observed with other SARS-CoV2 monoclonal antibodies and could occur with bebtelovimab. In addition, clinical worsening following administration of other SARS-CoV-2 monoclonal antibody treatment has been reported and therefore is possible with bebtelovimab. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19.
Side effects and it doesn't work. We are up against Big Pharma and the FDA, always have been.
(6)
(0)Scroll down for more posts ▼
